The Scientific Board of BioJeL

The Scientific Board of BioJeL is responsible for examining and validating all submitted requests according to a number of criteria.

Requests are analyzed in 3 stages:

  • Analysis of technical feasibility by the Technical Committee
  • Scientific evaluation by the Scientific Committee
  • Validation of the request by the Management Committee

The analytical criteria used by the Scientific Board for these evaluations relate to several items:

  • Technical feasibility (time, quantities)
  • Compatibility with the strategy of BioJeL (compatibility with the priority research programs defined by BioJeL and the Jérôme Lejeune Institute, with prioritization according to the type of request. For example, scientific partnerships are favoured over scientific services)
  • Checking of the legal and regulatory obligations of the person or entity making the request
  • Availability of samples with respect to consent (non-opposition, or agreement of the patient for the export of samples)
  • Agreement of the person or entity responsible for initiating the collection of the samples concerned
  • Priority given to the nature of the person or entity making the request (hospital establishment, national, international)
  • Availability with respect to the priority rights of other users (Is the collection in the process of constitution at the request of a researcher? Is the collection under embargo until the publication of the first results?)
  • Conditions of availability (billing, scientific partnership, industrial property rights)
  • Compatibility of the request with the ethics policy of the Jérôme Lejeune Institute and Foundation

Composition of the Technical Committee:

  • The Head of BioJeL

 Composition of the Scientific Board:

  • Professor Franck STURTZ – Professor of Biochemistry at the University of Limoges (France)
  • Professor Gérard LEFRANC – Professor of Immunology and Genetics and the University of Montpellier 2 (France)
  • Professor André MEGARBANE – Professor of Medical Genetics at the Faculty of Medicine of the University of Saint-Joseph in Beirut (Lebanon)
  • Doctor Aimé RAVEL – Pediatrician qualified in genetics and Head of Consultations at the Jérôme Lejeune Institute (France)

Composition of the Management Committee:

  • Jean-Marie SCHMITZ – President of the Jérôme Lejeune Institute
  • Grégoire FRANCOIS-DAINVILLE – General Director of the Jérôme Lejeune Institute
  • Jean-Marie LE MENE – President of the Jérôme Lejeune Foundation
  • Thierry de la VILLEJEGU – General Director